Buy 3 and get the 4th FREE!* | Learn More >>
9819
Arginase-1 Antibody
Primary Antibodies

Arginase-1 Antibody #9819

Reviews ()
Citations (14)

We recommend the following alternatives

# Product Name Application Reactivity
  • WB
  • IHC
  • IF
  • F
H M R XP

Supporting Data

REACTIVITY
SENSITIVITY
MW (kDa) 40
SOURCE Rabbit

Application Key:

  • W-Western
  • IP-Immunoprecipitation
  • IHC-Immunohistochemistry
  • ChIP-Chromatin Immunoprecipitation
  • IF-Immunofluorescence
  • F-Flow Cytometry
  • E-P-ELISA-Peptide

Species Cross-Reactivity Key:

  • H-Human
  • M-Mouse
  • R-Rat
  • Hm-Hamster
  • Mk-Monkey
  • Mi-Mink
  • C-Chicken
  • Dm-D. melanogaster
  • X-Xenopus
  • Z-Zebrafish
  • B-Bovine
  • Dg-Dog
  • Pg-Pig
  • Sc-S. cerevisiae
  • Ce-C. elegans
  • Hr-Horse
  • All-All Species Expected

Storage:

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

Arginase-1 Antibody recognizes endogenous levels of total arginase-1 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val47 of human arginase-1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

L-arginine plays a critical role in regulating the immune system (1-3). In inflammation, cancer and certain other pathological conditions, myeloid cell differentiation is inhibited leading to a heterogeneous population of immature myeloid cells, known as myeloid-derived suppressor cells (MDSCs). MDSCs are recruited to sites of cancer-associated inflammation and express high levels of arginase-1 (4). Arginase-1 catalyzes the final step of the urea cycle converting L-arginine to L-ornithine and urea (5). Thus MDSCs increase the catabolism of L-arginine resulting in L-arginine depletion in the inflammatory microenvironment of cancer (4,6). The reduced availability of L-arginine suppresses T-cell proliferation and function and thus contributes to tumor progression (4,6). Arginase-1 is of great interest to researchers looking for a therapeutic target to inhibit the function of MDSCs in the context of cancer immunotherapy (7). In addition, research studies have demonstrated that Arginase-1 distinguishes primary hepatocellular carcinoma (HCC) from metastatic tumors in the liver, indicating its value as a potential biomarker in the diagnosis of HCC (8,9).

  1. Albina, J.E. et al. (1989) J Exp Med 169, 1021-9.
  2. Mills, C.D. (2001) Crit Rev Immunol 21, 399-425.
  3. Rodriguez, P.C. et al. (2004) Cancer Res 64, 5839-49.
  4. Gabrilovich, D.I. and Nagaraj, S. (2009) Nat Rev Immunol 9, 162-74.
  5. Wu, G. and Morris, S.M. (1998) Biochem J 336 ( Pt 1), 1-17.
  6. Raber, P. et al. (2012) Immunol Invest 41, 614-34.
  7. Wesolowski, R. et al. (2013) J Immunother Cancer 1, 10.
  8. Sang, W. et al. (2015) Tumour Biol 36, 3881-6.
  9. Geramizadeh, B. and Seirfar, N. (2015) Hepat Mon 15, e30336.

Pathways & Proteins

Explore pathways + proteins related to this product.

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

To Purchase # 9819